trials
How progression-free survival is defined, why it matters as a clinical trial endpoint, and how it has appeared in the published tigilanol tiglate (EBC-46) human trial literature.
trials
How tigilanol tiglate trial designs have approached sample size estimation, the response-rate assumptions used, and what statistical power means for emerging EBC-46 evidence.
trials
How tigilanol tiglate clinical trials capture patient-reported quality-of-life data, what instruments are used, and how QoL fits alongside tumour-response endpoints.
trials
Tigilanol tiglate trials use modified RECIST 1.1 criteria for intratumoural agents. This article explains the measurement framework and how to interpret published response rates.
trials
How published QBiotics trial data describe serum cytokine and acute-phase reactant changes following intratumoral tigilanol tiglate, and the limits of biomarker prediction.